Aspiration risk with glucagon‐like peptide 1 ( GLP ‐1) agonists
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
We would like to draw attention to a concerning issue regarding the use of glucagon-like peptide 1 (GLP-1) agonists, commonly prescribed for diabetes management and weight loss, and their potential impact on gastric emptying and the associated aspiration risk. The GLP-1 agonist is an incretin, a naturally occurring peptide primarily synthesised in intestinal endocrine cells located in the terminal ileum and proximal colon. Upon nutrient ingestion, GLP-1 is rapidly released, engaging cAMP-linked GLP-1 receptors in various target tissues, including the pancreas (stimulating insulin release), the hypothalamus (stimulating satiety centres) and gastric neuronal cells (delaying gastric emptying). While endogenous GLP-1 has a short half-life of 2–3 min, pharmacological GLP-1 agonist analogues with extended durations of action have been developed for the management of diabetes mellitus (e.g. semaglutide, duraglutide, liraglutide) and weight management (e.g. semaglutide, liraglutide). Emerging evidence indicates a significant delay in gastric emptying associated with GLP-1 agonist use [1]. Furthermore, individuals with diabetes commonly experience impaired gastric emptying, with approximately 30–50% of long-standing diabetic patients exhibiting abnormally slow gastric emptying. Tachyphylaxis to delayed gastric emptying may occur with rapidly acting GLP-1 agonists administered by intravenous infusion [2]. However, there is evidence to suggest that longer acting GLP-1 agonists may impair gastric emptying for at least 8 weeks [3]. Moreover, patients utilising GLP-1 agonists for weight management may adopt intermittent drug regimens, including periods of drug ‘holidays’ between treatments. Studies suggest that both acute and intermittent use of GLP-1 agonists result in comparable impairment of gastric emptying [4]. Of particular concern to anaesthetists is the potential risk of aspiration associated with delayed gastric emptying. Several published case reports have documented instances of aspiration in patients receiving GLP-1 agonists, emphasising the importance of considering this risk [5]. However, the clinical significance of delayed gastric emptying induced by GLP-1 agonists remains incompletely understood. Additionally, the duration of the drug's effect and the timing of gastric emptying restoration following drug cessation require further investigation. Consideration should be given to performing gastric ultrasound to determine residual gastric content before induction of anaesthesia in these patients. However, it is important to note that there is currently a lack of evidence supporting the use of gastric ultrasound in this specific context. Therefore, further research efforts are warranted to elucidate the clinical significance of these effects and provide guidance on appropriate management strategies for patients receiving GLP-1 agonists who require anaesthesia and surgery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meier, J. J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.-V., Menge, B. A., Forst, T., & Kapitza, C. (2015) · Diabetes Care · doi:10.2337/dc14-1984 · Cited by 262
Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
Maselli, D. B., & Camilleri, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_496 · Cited by 248
Umapathysivam, M. M., Lee, M. Y., Jones, K. L., Annink, C. E., Cousins, C. E., Trahair, L. G., Rayner, C. K., Chapman, M. J., Nauck, M. A., Horowitz, M., et al. (2014) · Diabetes · doi:10.2337/db13-0893 · Cited by 193 · cited 1×
“Studies suggest that both acute and intermittent use of GLP-1 agonists result in comparableimpairmentofgastricemptying[4].”
BackgroundGulak, M. A., & Murphy, P. (2023) · Canadian Journal of Anesthesia/Journal canadien d'anesthésie · doi:10.1007/s12630-023-02521-3 · Cited by 153 · cited 1×
“Several published case reports have documented instances ofaspirationinpatientsreceivingGLP-1agonists,emphasising the importance of considering this risk [5].”
Background
Cited by
Hashash, J. G., Thompson, C. C., & Wang, A. Y. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.11.002 · Cited by 140
Ghusn, W., & Hurtado, M. D. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100127 · Cited by 122
“For instance, a new concern has been raised about the risk of aspiration in patients undergoing anesthesia due to the effect of these medications on gastric emptying [37 – 39].”
BackgroundAlkabbani, W., Suissa, K., Gu, K. D., Cromer, S. J., Paik, J. M., Bykov, K., Hobai, I., Thompson, C. C., Wexler, D. J., & Patorno, E. (2024) · BMJ · doi:10.1136/bmj-2024-080340 · Cited by 60
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025) · Biomolecules · doi:10.3390/biom15030408 · Cited by 58
“Patients have also been reported to take “drug holidays” in which they pause the use of the drug intermittently for special occasions, but there is very little in the literature on this [278].”
Chang, M. G., Ripoll, J. G., Lopez, E., Krishnan, K., & Bittner, E. A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216336 · Cited by 43
Metadata
- Authors
- Marroquin‐Harris, M., & Olesnicky, B.
- Venue
- Anaesthesia
- Publisher
- Wiley
- Published
- 2023-07-13
- Volume
- 78
- Issue
- 12
- Pages
- 1524-1524
- ISSN
- 0003-2409 (ISSN-L)
- 1365-2044
- OpenAlex
- W4384277104
- Cited by
- 20
- References
- 4
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aspiration risk with glucagon‐like peptide 1 ( GLP ‐1) agonists. https://app.cochat.ai/papers/10.1111/anae.16099
- The paper
- Marroquin‐Harris, M., & Olesnicky, B. (2023). Aspiration risk with glucagon‐like peptide 1 ( GLP ‐1) agonists. Anaesthesia. https://doi.org/10.1111/anae.16099
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.